BioHarvest Sciences Launch New Botanical Synthesis CDMO

• BioHarvest Sciences has launched a new Contract Development and Manufacturing Organization (CDMO) business unit specialising in Botanical Synthesis

• The new unit has signed two contracts to develop complex molecules for a NASDAQ listed pharmaceutical company and a company in the nutrition and ingredients industry.

• The Botanical Synthesis process technology will be offered to customers in three major steps, with Non-Recurring Engineering Expenses (NRE) ranging from US$150k to US$2.5M.

BioHarvest Sciences, a biotechnology company focused in Botanical Synthesis process technology, has announced the official launch of its new Contract Development and Manufacturing Organisation (CDMO) business unit.

The company has also announced that this new unit has recently signed two contracts to develop complex molecules. The clients include a NASDAQ listed pharmaceutical company and a company in the nutrition and ingredients industry.

BioHarvest’s Botanical Synthesis Process is capable of developing complex molecules, otherwise known as Biologics. These Biologics have a number of unique advantages for the industry, including lower costs of development and manufacturing, a much faster speed of development, and non-immunogenic properties that enhance safety. As a result of these advantages, the company has decided to call these unique plant-derived complex molecules BIOLOGICS +.

The CDMO business offers the Botanical Synthesis process technology in three major steps to its customers. The first step, which lasts 3 to 6 months, is capable of producing a small biomass of the plant-based BIOLOGICS + from the source plant. The second step, lasting 6 to 9 months, provides for delivery of an increased amount of biomass to enable clinical trials and other tests. The final step, lasting 9 to 12 months, brings the molecules to a large scale production capability.

Ilan Sobel, CEO, said “Our mission to turn thousands of plants into scientifically reliable sources of therapeutic molecules will be accelerated by our CDMO business model. The launch of this new business unit will, for the first time, offer our proprietary Botanical Synthesis process technology to pharmaceutical companies as well as to other key industry verticals who are actively searching for new complex molecules to drive their innovation and growth agendas. These two contracts with established industry players are a major validation of the critical market need for our Botanical Synthesis Process and Biologics⁺ molecules.”